dc.contributor.author | Molina-Arcas, M | |
dc.contributor.author | Samani, A | |
dc.contributor.author | Downward, J | |
dc.coverage.spatial | Switzerland | |
dc.date.accessioned | 2022-09-13T13:54:18Z | |
dc.date.available | 2022-09-13T13:54:18Z | |
dc.date.issued | 2021-06-10 | |
dc.identifier | ARTN 899 | |
dc.identifier | genes12060899 | |
dc.identifier.citation | Genes, 2021, 12 (6), pp. 899 - | |
dc.identifier.issn | 2073-4425 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5457 | |
dc.identifier.eissn | 2073-4425 | |
dc.identifier.eissn | 2073-4425 | |
dc.identifier.doi | 10.3390/genes12060899 | |
dc.description.abstract | Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its 'switch-II pocket' have allowed development of effective mutant-specific inhibitors. Currently seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we discuss historical efforts to target RAS directly and approaches to target RAS effector signalling, including combinations that overcome limitations of single-agent targeting. We also review pre-clinical and clinical evidence for the efficacy of KRAS-G12C inhibitor monotherapy followed by an illustration of combination therapies designed to overcome primary resistance and extend durability of response. Finally, we briefly discuss novel approaches to targeting non-G12C mutant isoforms. | |
dc.format | Electronic | |
dc.format.extent | 899 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | MDPI | |
dc.relation.ispartof | Genes | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | KRAS-G12C | |
dc.subject | RAS | |
dc.subject | cancer | |
dc.subject | oncogene | |
dc.subject | targeted therapy | |
dc.subject | Animals | |
dc.subject | Antineoplastic Agents | |
dc.subject | Enzyme Inhibitors | |
dc.subject | Humans | |
dc.subject | Mutation | |
dc.subject | Neoplasms | |
dc.subject | ras Proteins | |
dc.title | Drugging the Undruggable: Advances on RAS Targeting in Cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-06-04 | |
dc.date.updated | 2022-09-13T13:53:29Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.3390/genes12060899 | |
rioxxterms.licenseref.startdate | 2021-06-10 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/34200676 | |
pubs.issue | 6 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Lung Cancer Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Lung Cancer Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/18/19 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.3390/genes12060899 | |
pubs.volume | 12 | |
icr.researchteam | Trans Immunotherapy | |
icr.researchteam | Lung Cancer Group | |
dc.contributor.icrauthor | Samani, Amit | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-13. Deposit type is initial. No. of files: 1. Files: Drugging the Undruggable Advances on RAS Targeting in Cancer. .pdf | |